Remove Contract Manufacturing Remove Hormones Remove Protein
article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

article thumbnail

Outsourcing Peptide Synthesis: Preferred Choice of Drug Developers

Roots Analysis

They also play important roles in antibiotics , toxins, hormones, and enzymes. These versatile molecules serve various diverse roles, functioning as neurotransmitters, growth factors, ion channel ligands, hormones, anti-infectives, and more. When introduced into the body, lab-synthesized peptides become active.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HPAPIs – Current Interest of the Pharmaceutical Industry

Roots Analysis

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. The ADCs bind to specific proteins or peptides in cancer cells with very high specificity and efficacy influencing the biological functions.

article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

“Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Hospital products, which grew 10% operationally to $2.3 down 7%, which reflects relatively stable U.S. A decision from the EC is expected in 2022.